Sonnet BioTherapeutics Releases Virtual Investor '"What this Means" Segment

2 days ago

Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company's recent issuance of a U.S. patent covering a variant of IL-18 incorporated into two novel immunotherapeutic drug candidates, SON-1400 and ...

Ticker	Sentiment	Impact
SONN	Neutral	14 %